These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29869168)

  • 1. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
    Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
    Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy.
    Jung G; Brandl M; Eisner W; Fraunberger P; Reifenberger G; Schlegel U; Wiestler OD; Reulen HJ; Wilmanns W
    Int J Cancer; 2001 Jan; 91(2):225-30. PubMed ID: 11146449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
    Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
    Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
    [No Abstract]   [Full Text] [Related]  

  • 4. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
    Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumour cell lysis by a bispecific antibody recognising epidermal growth factor receptor (EGFR) and CD3.
    Knuth A; Bernhard H; Jäger E; Wölfel T; Karbach J; Jäggle C; Strittmatter W; Meyer zum Büschenfelde KH
    Eur J Cancer; 1994; 30A(8):1103-7. PubMed ID: 7654439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.
    Tapia-Galisteo A; Sánchez Rodríguez Í; Aguilar-Sopeña O; Harwood SL; Narbona J; Ferreras Gutierrez M; Navarro R; Martín-García L; Corbacho C; Compte M; Lacadena J; Blanco FJ; Chames P; Roda-Navarro P; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2022; 11(1):2034355. PubMed ID: 35154908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR Fibronectin Bispecific Chemically Self-Assembling Nanorings (CSANs) Induce Potent T Cell-Mediated Antitumor Responses and Downregulation of EGFR Signaling and PD-1/PD-L1 Expression.
    Kilic O; Matos de Souza MR; Almotlak AA; Wang Y; Siegfried JM; Distefano MD; Wagner CR
    J Med Chem; 2020 Sep; 63(18):10235-10245. PubMed ID: 32852209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.
    Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M
    MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
    Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
    Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
    Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
    MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
    Satta A; Grazia G; Caroli F; Frigerio B; Di Nicola M; Raspagliesi F; Mezzanzanica D; Zaffaroni N; Gianni AM; Anichini A; Figini M
    Front Immunol; 2019; 10():2514. PubMed ID: 31708930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
    Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
    Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
    Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
    Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.